Ipsen SA ADR (IPSEY PINK) stock market data APIs
$35.1519
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
Ipsen SA ADR Financial Data Overview
Price chart is built with
Anychart
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Prev. Close
35.1519
Open
35.1519
High
35.1519
Low
35.1519
52 wk Range
25.3212-35.075
Market Cap
11 595 M
P/E Ratio
22.3408
Shares Outstanding
331 M
Revenue
3 760 M
EPS
4
Dividends (Yield)
0.0402
Beta
0.19
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ipsen SA ADR data using free add-ons & libraries
Get Ipsen SA ADR Fundamental Data
Ipsen SA ADR Fundamental data includes:
- Net Revenue: 3 760 M
- EBITDA: 1 333 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ipsen SA ADR News
New
Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen Pharma Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Art...
Ipsen (ENXTPA:IPN): Exploring Current Valuation After Recent Share Price Gains
Ipsen (ENXTPA:IPN) is back on investors’ radar, and not because of any one specific headline. Sometimes, a stock’s recent price swings themselves are the story, especially when they diverge from a...
Ipsen (ENXTPA:IPN) Gains Canadian Approval For Bylvay In Treating Alagille Syndrome
Ipsen recently celebrated a significant milestone with Health Canada's approval of Bylvay™ (odevixibat) for treating cholestatic pruritus in Alagille Syndrome patients. This product-related developm...
Is There Now an Opportunity in Ipsen After Latest FDA Approval?
Thinking about what to do with your Ipsen shares right now? You are not alone. With a steady climb in the share price over recent weeks, up 1.7% in the past week and a notable 11.9% over the last mont...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
